Skip to main content
Evaluating lymphocyte subsets and cytokine levels in blood samples from 53 patients with systemic JIA revealed significa

ACR_Journals ACR_Journals

1 year 2 months ago
Evaluating lymphocyte subsets and cytokine levels in blood samples from 53 patients with systemic JIA revealed significant differences across sJIA clinical phenotypes, with dynamic changes linked to treatment response over time ACR Open Rheumatology https://t.co/GU5y70EXiI https://t.co/oCiKd0INuT
🧵 Vasculitis is Not One Disease – It’s a Spectrum
It’s not a diagnosis.
It’s a mechanism.
From small-vessel p

Aravind Palraj Rheumat_Aravind

1 year 2 months ago
🧵 Vasculitis is Not One Disease – It’s a Spectrum It’s not a diagnosis. It’s a mechanism. From small-vessel purpura to large-vessel aneurysms, here’s how to recognize and reason through the vasculitis spectrum👇 @Amansharmapgi @DurgaPrasannaM1 @12VRavindran @Kanjivellam https://t.co/eEalTpDTGD
Full read review of DMARD effects on CV Risks. Strongest CV protective effects for MTX & TNF inhibitors. Potentiall

Dr. John Cush RheumNow

1 year 2 months ago
Full read review of DMARD effects on CV Risks. Strongest CV protective effects for MTX & TNF inhibitors. Potentially beneficial are sulfasalazine, hydroxychloroquine, & leflunomide. More info needed on IL-6, IL-17/23 inhibitors. Concerns over NSAIDs & JAKi https://t.co/INEdCt0pxa
Large metanalysis of TNFi use in immune-mediated inflammatory diseases (45 studies, 150K pts) shows no increased risk of

Dr. John Cush RheumNow

1 year 2 months ago
Large metanalysis of TNFi use in immune-mediated inflammatory diseases (45 studies, 150K pts) shows no increased risk of de novo heart failure (HF), and no significant risk of HF worsening w/ TNFis. https://t.co/9sRVsMZ1kv https://t.co/Kapg9ZwVGf
The British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) have published a guideline for the management of adults with ANCA-associated vasculitis (AAV); specifically three conditions: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA).
Study of 110 #SLE pts found 41% w/ osteoporosis, 35% of whom had Lupus nephritis (LN). SLE w/ lower BMD assoc w/ LN clas

Dr. John Cush RheumNow

1 year 2 months ago
Study of 110 #SLE pts found 41% w/ osteoporosis, 35% of whom had Lupus nephritis (LN). SLE w/ lower BMD assoc w/ LN classes III & IV, U1-RNP Abs, high CRP, & longer Dz duration, also w/ higher age, HAQ, C3 levels. 86% were on glucocorticoids, mean age 48 yrs. https://t.co/dqutqbvnjB
RHEUMATOLOGIST Survey: How has your career/practice evolved in the last 20 years? Click here>>https://t.co/wyKkd

Dr. John Cush RheumNow

1 year 2 months ago
RHEUMATOLOGIST Survey: How has your career/practice evolved in the last 20 years? Click here>>https://t.co/wyKkdUQclz a. just getting started… b. More research &scholarship c. Growing a successful practice d. Greater knowledge and expertise e. Closer to burn-out
French retrospective observational study of Bx/CT/PET Dx of 380 #GCA pts found 7.6% (29) w/ Nl baseline CRP < 10

Dr. John Cush RheumNow

1 year 2 months ago
French retrospective observational study of Bx/CT/PET Dx of 380 #GCA pts found 7.6% (29) w/ Nl baseline CRP < 10 mg/L at Dx. GCA w/ low CRP had less fever, more ocular Dz (ant ischemic optic neuropathy 28 vs 13%), & limb claudication (24 vs. 8%) but equal relapse rates https://t.co/fPy92NjJzS
Annals of Family Medicine pub a machine learning study that predicts clinic "no-shows" w/ 85% accuracy & late cancel

Dr. John Cush RheumNow

1 year 2 months ago
Annals of Family Medicine pub a machine learning study that predicts clinic "no-shows" w/ 85% accuracy & late cancellations w/ 92% accuracy. Data derived from >1.1 million appointments from 15 family medicine clinics in Pennsylvania between 2019 and 2023. https://t.co/462fwmEGJl https://t.co/n5vIbtKFu0
CCL17 is a downstream mediator of GM-CSF. Drug repurposing review of FDA approved Rx shows 5 Rx w/ anti-CCL17 effects -

Dr. John Cush RheumNow

1 year 2 months ago
CCL17 is a downstream mediator of GM-CSF. Drug repurposing review of FDA approved Rx shows 5 Rx w/ anti-CCL17 effects - fluoxetine, ractopamine, ponesimod, terbutaline & etravirine, w/ inhibition of STAT5, IRF4 & CCL17 & shows antiinflamm effects in RA animal model https://t.co/2aTyZMWPJn
RheumNow's August 2025 “Live Vote” surveys examine Rheumatologist impressions, knowledge and practices over the last 20 years when treating rheumatoid arthritis. The first survey on RA Treatment (7/28/2025) sheds light on evolving prescribing habits, use of biologics, and key frustrations in RA care.
FDA Approves Vagal Nerve Stimulator for RA

SetPoint Medical announced the FDA approved the SetPoint System, a neuroimm

Dr. John Cush RheumNow

1 year 2 months ago
FDA Approves Vagal Nerve Stimulator for RA SetPoint Medical announced the FDA approved the SetPoint System, a neuroimmune modulation treatment for moderate-to-severe rheumatoid arthritis (RA), for patients not well-managed or cannot tolerate—existing RA therapies like https://t.co/McheSz30dl
Aging Quiets Lupus
  • EurekAlert!
UCSF researchers have found that epigentic changes in interferon genes over time may lead to lupus being less active as they age. Lupus is a “classic” autoimmune disease. It causes the immune system’s first-line viral defenses — known as interferons — to attack the body. Nearly every organ is at risk, leading to conditions like kidney and heart disease. But unlike many other autoimmune or chronic illnesses, lupus can improve as patients reach
TriNetX study of E-health record study of ~53k transcatheter aortic valve intervention (TAVI) pts. 705 were on preoperat

Dr. John Cush RheumNow

1 year 2 months ago
TriNetX study of E-health record study of ~53k transcatheter aortic valve intervention (TAVI) pts. 705 were on preoperative colchicine - these had signif reduction of post-TAVI heart block and AV/LBBB (RR 0.867 [95% CI, 0.756–0.994]) @ 1 month, but not at 6 months https://t.co/9tI2KFY7u7
×